title: Immunological unresponsiveness to hepatic allografts in rats. Immunological reactivities of the recipient to donor antigens.
abstract: Wistar (RT1bv1) rats transplanted orthotopically with ACI (RT1a) livers survive indefinitely without any immunosuppression, while heterotopic heart grafts or skin grafts are rejected acutely in this combination. Levels of alkaline phosphatase after liver allografting remain significantly higher than those found in controls receiving syngeneic grafts. We studied changes in immune responsiveness in rats receiving liver grafts. Local graft-versus-host reactivity was present at all times assayed. Delayed type hypersensitivity reactions were already positive 2 weeks after liver transplantation and increased in strength. Liver graft-bearing rats were subsequently grafted with donor or third-party skin. Third-party skin grafts survived significantly longer on liver-grafted rats than on untreated controls when grafted within the first week after grafting. Donor-type skin grafts survived longer than controls when grafted within the first 4 weeks after liver grafting, although the skin grafts were eventually rejected. Donor-type skin grafted more than 8 weeks after liver grafting was rejected acutely. In an adoptive transfer assay, ACI hearts survived significantly longer in Wistar rats given serum from Wistar donors 2-4 weeks after ACI liver grafts than in untreated controls. On the other hand, spleen cells obtained at any period after liver grafting were not capable of prolonging cardiac allograft survival after transfer to syngeneic recipients. Thus cellular responses to ACI antigen are not changed during the life-span of liver-grafted animals. Evidence suggests that a serum "enhancing" factor protects the donor liver from rejection in the initial period after liver transplantation. The long-term acceptance of liver grafts is discussed.
authors.affiliation: Second Department of Surgery, Osaka University Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hasuike
authors.forename: M
authors.initials: M
authors.lastname: Monden
authors.forename: L A
authors.initials: LA
authors.lastname: Valdivia
authors.forename: N
authors.initials: N
authors.lastname: Kubota
authors.forename: Y
authors.initials: Y
authors.lastname: Nakano
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: T
authors.initials: T
authors.lastname: Mori
mesh_terms: D000818:Animals; D001663:Bilirubin / Q000097:blood; D006085:Graft Survival; D006087:Graft vs Host Reaction; D007108:Immune Tolerance; D007519:Isoantigens / Q000008:administration & dosage* / Q000276:immunology; D016031:Liver Transplantation; D008198:Lymph Nodes / Q000276:immunology; D008297:Male; D051381:Rats; D011912:Rats, Inbred ACI; D011916:Rats, Inbred F344; D011919:Rats, Inbred Strains; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000401:mortality
chemical_list: D007519:Isoantigens; D001663:Bilirubin